Did you know colitis affects 30-45% of patients on CTLA-4 inhibitors like ipilimumab (Yervoy)? Symptoms include bloating, cramping, and diarrhea. Most cases are manageable, but it's vital to stay informed! aimatmelanoma.org/side-effect-ce…

In this compelling episode of “Surviving the Spotlight,” we sit down with Jessica Gilstrap, a melanoma survivor and independent filmmaker, whose inspiring journey from cancer diagnosis to creative success is both moving and motivating. aimatmelanoma.org/surviving-the-…

We last discussed vaccines in September 2021, and in the three years since, remarkable progress has been made in cancer immunotherapy, including promising vaccines for cancer treatment. aimatmelanoma.org/in-plain-engli…

🗓 Date: Saturday, November 2, 2024 🕚 Time: 11:00 AM ET | 10:00 AM CT | 9:00 AM MT | 8:00 AM PT 💻 Format: Presented Virtually REGISTER: bit.ly/3O3D55z

Join Dr. Geoffrey Lim as he interviews Dr. Jason Luke about adjuvant therapy options. Explore our latest flip magazine for the newest advancements in adjuvant therapy bit.ly/4eaGR7N #Melanoma #AdjuvantTherapy #OncologyInsights

Moffitt Study Shows Immune Structures in Melanoma Could Help Predict Patient Survival moffitt.org/newsroom/news-…

BREAKING NEWS>>Replimune has submitted a Biologics License Application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) combined with nivolumab for the treatment of advanced melanoma in adults. bit.ly/3AKr9ma

Big news! The FDA has approved Opdivo Qvantig (nivolumab) as a subcutaneous injection for various solid tumors, including melanoma, lung cancer, and renal cell carcinoma. More convenience and flexibility for patients! aimatmelanoma.org/bristol-myers-…

Honoring the legacy of President Jimmy Carter, whose brave journey with melanoma inspired millions. His strength, grace, and openness about his battle continue to raise awareness and offer hope. Thank you, President Carter, for showing us true resilience. #JimmyCarter

The FDA has accepted the BLA for RP1 (vusolimogene oderparepvec) + nivolumab for advanced melanoma. With Priority Review granted, we’re one step closer to offering hope to patients who have failed previous treatments. Learn more: bit.ly/42ndXyN

last night's Tri-State Melanoma Consortium – Inaugural Convening aimatmelanoma.org/tri-state-mela…

Explore real-world cases and insights on immunotherapy in unresectable & resectable #Melanoma in this #MedEd activity from #ASCO2025, featuring Dr. Hussein Tawbi, Prof. Paolo Antonio Ascierto, & Bella Glitza, MD, PhD, with PeerView bit.ly/3TclQkY

FDA rejects Replimune’s RP1 therapy for advanced skin cancer.The trial was “not considered an adequate and well-controlled investigation providing substantial evidence of effectiveness.” A sign of the agency’s tougher stance under Vinay Prasad.bit.ly/45fBEtY

The FDA said no to a new treatment for advanced melanoma. We're collecting stories to help them understand what that means for real people. Share your voice: bit.ly/4f78kJi #Melanoma #PatientVoices #FDA #AIMatMelanoma

New results show a potential new option for advanced melanoma. Cylembio + KEYTRUDA helped patients live longer without disease progression vs. KEYTRUDA alone — especially in those with fewer treatment options. Full update: bit.ly/45qqYaJ

“My wife just finished treatment, and it’s not working. Tumors are spreading. She can’t continue Opdivo & Yervoy. We need the FDA to approve RP-1.” — B.S., NJ Stories like this show why families urgently need more treatment options. #PatientVoices #FDA #EndMelanoma

At AIM at Melanoma, we know that rare forms of melanoma are often underrepresented in clinical trials. Here’s one patient’s story that shows why advancing treatments and access is so critical. #FDA

We need decision-makers to reconsider—patients and families cannot afford to lose access to promising treatments. Please share this message so our voices are heard. #FDA U.S. FDA

Excellent discussion with⁩ Peter Warren from the Houston Chronicle. Today’s experimental therapy on clinical trials is tomorrow’s standard of care! Source: Houston Chronicle share.google/g9oibbE6oHh3pW…

"My husband is 43. We have 2 little kids. He’s Stage 4 melanoma. Replimune was our back-up hope. Denying this drug takes away options—and hope is part of the cure. Please reconsider."— Wife, mother & caregiver AIM at Melanoma stands with families like hers.